Display options
Cite
Mondaini N. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?. World J Mens Health. 2020;38(3):254-255doi: 10.5534/wjmh.200089.
Mondaini, N. (2020). Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?. The world journal of men's health, 38(3), 254-255. https://doi.org/10.5534/wjmh.200089
Mondaini, Nicola. "Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?." The world journal of men's health vol. 38,3 (2020): 254-255. doi: https://doi.org/10.5534/wjmh.200089
Mondaini N. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?. World J Mens Health. 2020 Jul;38(3):254-255. doi: 10.5534/wjmh.200089. PMID: 32573126; PMCID: PMC7308240.
Copy Download .nbib Format: NLM
Share it on

World J Mens Health. 2020 Jul;38(3):254-255. doi: 10.5534/wjmh.200089.

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?.

The world journal of men's health

Nicola Mondaini

Affiliations

  1. Urology Unit, Villa Donatello Hospital, Florence, Italy. [email protected].

PMID: 32573126 PMCID: PMC7308240 DOI: 10.5534/wjmh.200089

[No abstract available.]

Conflict of interest statement

The author has nothing to disclose.

References

  1. Lancet. 2020 May 2;395(10234):1417-1418 - PubMed
  2. JMIR Public Health Surveill. 2020 May 13;6(2):e19199 - PubMed
  3. Crit Care Resusc. 2020 Apr 15;: - PubMed
  4. Drug Dev Res. 2018 Dec 13;: - PubMed
  5. Int J Infect Dis. 2020 May;94:91-95 - PubMed
  6. N Engl J Med. 2010 Aug 12;363(7):620-8 - PubMed
  7. Diabetes Metab Syndr. 2020 May 6;14(4):535-545 - PubMed

Publication Types